imiquimod has been researched along with Hepatitis C, Chronic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aoki, Y; Hiramine, S; Imamura, M; Ito, K; Kanto, T; Kimura, T; Kirikae, I; Korenaga, M; Masaki, N; Matsui, T; Mizokami, M; Murata, K; Saito, H; Sugiyama, M; Yoshio, S | 1 |
| Averett, D; Fletcher, S; Steffy, K | 1 |
1 review(s) available for imiquimod and Hepatitis C, Chronic
| Article | Year |
|---|---|
Masked oral prodrugs of toll-like receptor 7 agonists: a new approach for the treatment of infectious disease.
Topics: Administration, Oral; Aminoquinolines; Animals; Guanosine; Hepatitis C, Chronic; Humans; Imiquimod; Prodrugs; Toll-Like Receptor 7 | 2006 |
1 other study(ies) available for imiquimod and Hepatitis C, Chronic
| Article | Year |
|---|---|
Ex vivo induction of IFN-λ3 by a TLR7 agonist determines response to Peg-IFN/ribavirin therapy in chronic hepatitis C patients.
Topics: Aged; Aminoquinolines; Antiviral Agents; Cells, Cultured; Dendritic Cells; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Imiquimod; Interferon-alpha; Interferons; Interleukins; Leukocytes, Mononuclear; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Ribavirin; RNA, Messenger; Toll-Like Receptor 7; Treatment Outcome | 2014 |